{"id":"W4412956201","doi":"10.1158/1535-7163.mct-24-1176","title":"Preclinical Pharmacokinetic, Pharmacodynamic, and Safety Profile of OBI-992: A Novel TROP2-Targeted Antibody–Drug Conjugate","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"FSD Pharma (Canada)","funders":"National Applied Research Laboratories","keywords":"Pharmacology; Medicine; Pharmacokinetics; In vivo; Toxicity; Pharmacodynamics; Drug; Antibody; Cancer research; Cell culture; Immunology; Internal medicine; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005916606,0.0003286232,0.0006503995,0.0002269185,0.00007875745,0.00003000837,0.0003283532,0.0001495824,0.0004046004],"category_scores_gemma":[0.00003921828,0.0003026072,0.0001947043,0.0005987763,0.0003657597,0.00004986006,0.000124891,0.0006576249,0.000007002428],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001658976,"about_ca_system_score_gemma":0.0007520476,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001399519,"about_ca_topic_score_gemma":0.00001042209,"domain_scores_codex":[0.9972717,0.0002256433,0.0006879325,0.0005802715,0.0006918244,0.0005426623],"domain_scores_gemma":[0.9986346,0.0001602189,0.0001561037,0.0005169515,0.0003531716,0.0001789168],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001835056,0.0005344047,0.00563969,0.0009433854,0.0009572668,0.00007235431,0.0003551344,0.00004461666,0.951355,0.000483182,0.0004763301,0.03730359],"study_design_scores_gemma":[0.01747341,0.0006322514,0.0151145,0.001006231,0.001932765,0.00005045443,0.0001632989,0.02252558,0.8083454,0.000300072,0.1318271,0.000628984],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9054723,0.04121951,0.01803895,0.01696982,0.0009716292,0.00429808,0.0007683085,0.0001983445,0.012063],"genre_scores_gemma":[0.9810237,0.0076047,0.002308797,0.007583932,0.0001109413,0.000160584,0.00009364937,0.00007058016,0.001043145],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1430096,"threshold_uncertainty_score":0.9999426,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03920731020912873,"score_gpt":0.4259494892401876,"score_spread":0.3867421790310588,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}